




Contents lists available at [ScienceDirect](#)

Journal of Clinical & Translational Endocrinology

journal homepage: www.elsevier.com/locate/jcte



Corrigendum

Corrigendum to “Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals” [J. JCTE 2 (2015) 55–60]

Jamie D. Weinand, Joshua D. Safer^{*}

Transgender Medicine Research Group, Section of Endocrinology, Diabetes and Nutrition, Boston University School of Medicine, Boston, MA, USA

In volume 2 of JCTE, page 57, in the first paragraph, the word androgen was inadvertently replaced with the word estrogen on 2 occasions. The sentence should read “In Kuroda et al. (2008), no breast carcinoma was found among FTM individuals (n = 56) who had been on

androgen for an average of 11 months, while one breast carcinoma was found in among those FTM individuals (n = 130) who were not on androgen”.

The authors apologise for the inconvenience caused.



DOI of original article: <https://doi.org/10.1016/j.jcte.2015.02.003>.

^{*} Corresponding author at: Transgender Medicine Research Group, Section of Endocrinology, Diabetes and Nutrition, Boston University School of Medicine, 715 Albany Street, Room M-1016, Boston, MA 02118, USA.

E-mail address: jsafer0115@gmail.com (J.D. Safer).

<https://doi.org/10.1016/j.jcte.2024.100334>

Available online 16 March 2024

2214-6237/© 2024 The Author(s). Published by Elsevier Inc. All rights reserved.